Project overview

Active Biotech operations are currently primarily focused on the laquinimod projects:

Laquinimod is a quinoline compound under development for the treatment of multiple sclerosis (MS) and Huntington’s disease. Active Biotech has an agreement with the Israeli company Teva Pharmaceutical Industries Ltd (June 2004) covering the development and commercialization of laquinimod.

Only commercial activities are performed with respect to the projects with tasquinimod, paquinimod, ANYARA and SILC.